KITE 363
Alternative Names: KITE-363Latest Information Update: 15 Nov 2021
At a glance
- Originator Kite Pharma
- Developer Gilead Sciences; Kite Pharma
- Class Cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 05 Nov 2021 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT04989803)
- 31 Aug 2021 The US FDA approves IND application for KITE 363 in B-cell lymphoma
- 01 Aug 2021 Kite Pharma plans a phase I trial for Diffuse large B cell lymphoma (Second line or greater therapy, In adults, In the Elderly) (IV, Infusion) in August 2021 (NCT04989803)